| VEGF Inhibitor KH902 Suppresses Choroidal Neovascularization in Laser Injury Cynomolgus Monkeys
Ming Zhang1,Qingjie Xia1,Bin Liu1, Dan Meng1, Junjun Zhang1, Dan Meng1, Mi Yan1 Chun Yang2, Ziyu Jiang2, Dechao Yu2 *
1 West China Hospital，Sichuan University， Chengdu, 610041 P.R.China;
2 Kanghong Biotechnologies, Inc., No. 36 Shuxi Rd., Jinniu Distriction, Chengdu, P.R. China
* Corresponding author E-mail: yudechao@cn-kanghong.com
BCKGROUND Vascular endothelial growth factor (VEGF) plays a central role in the development of retinal neovascularization and diabetic macular edema. There is also evidence suggesting that VEGF is an important stimulator for choroidal neovascularization in aged macular degeneration (AMD). KH902 is a humanized antibody-liked molecule designed to bind VEGF. This protein was suggested to supress the neovascularizations.
PURPOSE To investigate the effect of KH902 in a model for experimental choroidal neovascularization in the cynomolgus monkey eye intravitreal injections of.
METHODS Choroidal neovascularization was induced by laser injury as 5-7 ruptures per eye of Bruch’s membrane in both eyes of cynomolgus monkeys and followed with weekly intravitreal injections of KH902(640 ug/eye; n= 4/group) or PBS. Photography and fluorescein angiography were carried out three weeks later. Fluorescein angiograms were graded using a masked standardized protocol. The data were analyzed with SPSS10.0.
RESULTS In the intravitreal injections of PBS control group, strong fluoroscein leakage was seen in 45% laser injury spot (5/11, 2 eyes), but in the KH902 treated group the ratio decreased significantly to 8.6% (2/23, 4 eyes) (p<0.05) and the leakage was very less.
CONCLUSIONS This study has demonstrated that KH902 has a strong supression on choroidal neovascularization and may provide a new agent for consideration for treatment of patients with choroidal neovascularization.
【Key words】Choroidal Neovascularization, KH902, antiangiogenesis
|
